Greater Cannabis Company (GCAN) Other Non-Current Liabilities (2016 - 2021)
Greater Cannabis Company's (GCAN) quarterly Other Non-Current Liabilities came in at $260905.0 in Q1 2021, down 84.69% year-on-year from $1.7 million in Q1 2020, and up 1395.93% quarter-over-quarter from $17441.0 in Q4 2020.
Greater Cannabis Company (GCAN) Other Non-Current Liabilities (2016 - 2021) Analysis & Trends
Greater Cannabis Company's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $260905.0 for Q1 2021.
- On a quarterly basis, Other Non-Current Liabilities fell 84.69% year-over-year to $260905.0 in Q1 2021; TTM through Mar 2021 was $260905.0, a 84.69% decrease from a year earlier, with the FY2020 full-year figure at $17441.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities climbed to $260905.0 in Q1 2021 per GCAN's latest filing, from $17441.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $1.7 million in Q1 2020 and bottomed at $17441.0 in Q4 2019.
- The 5-year median for Other Non-Current Liabilities is $259142.0 (2018), against an average of $343527.9.
- Across the five-year window, Other Non-Current Liabilities soared 411.19% in 2020 and sank 84.69% in 2021, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $205403.0 in 2017, then tumbled by 47.21% to $108427.0 in 2018, then slumped by 83.91% to $17441.0 in 2019, then changed by 0.0% to $17441.0 in 2020, then jumped by 1395.93% to $260905.0 in 2021.
- Per Business Quant, the three latest GCAN Other Non-Current Liabilities figures stand at $260905.0 (Q1 2021), $17441.0 (Q4 2020), and $325935.0 (Q3 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 260,905.00 |
| Dec 31, 2020 | 17,441.00 |
| Sep 30, 2020 | 325,935.00 |
| Jun 30, 2020 | 539,686.00 |
| Mar 31, 2020 | 1.70 Mn |
| Dec 31, 2019 | 17,441.00 |
| Sep 30, 2019 | 251,367.00 |
| Jun 30, 2019 | 251,367.00 |
| Mar 31, 2019 | 333,432.00 |
| Dec 31, 2018 | 108,427.00 |
| Sep 30, 2018 | 482,667.00 |
| Jun 30, 2018 | 270,502.00 |
| Mar 31, 2018 | 259,142.00 |
| Dec 31, 2017 | 205,403.00 |
| Sep 30, 2017 | 124,731.00 |
| Dec 31, 2016 | 100,000.00 |